Skip to main content Skip to main navigation menu Skip to site footer

Hemangioma activity score evaluation in infantile hemangioma patients: a retrospective study

  • Putri Halla Shavira ,
  • Muhammad Yulianto Listiawan ,
  • Sawitri ,
  • Cita Rosita Sigit Prakoeswa ,
  • Rahmadewi ,
  • Linda Astari ,
  • Budi Utomo ,
  • Ni Putu Susari Widianingsih ,

Abstract

Introduction: Infantile hemangioma (IH) is a benign vascular tumor commonly found in children. Generally, no special therapy is required because spontaneous resolutions occur. However, in some cases, therapy is required due to the potential of complications. During therapy, the side effects and effectiveness of therapy must be evaluated. One of the assessment tools is the Hemangioma Activity Score (HAS). HAS is a simple and objective assessment to evaluate the successful treatment of IH by observing swelling, color, and ulceration. The use of HAS in Indonesia is still minimal. This study aims to evaluate HAS before and after therapy in IH patients at Dr. Soetomo General Academic Hospital and Surabaya Skin Centre.

Methods: Twenty-seven patient medical records were selected based on the inclusion and exclusion criteria. This study is an analytic cross-sectional retrospective using consecutive sampling. The collected data were tested for suitability using Cohen's Kappa. Pre- and post-tests were carried out using the Shapiro-Wilk and Wilcoxon tests afterward.

Results: Among 27 IH cases occurred in females (81.4%), with the youngest age of the patient being 1 month and the oldest being 8 years. The onset of lesions in all patients appeared before 1 year of age. The most frequent location for IH lesions was the facial area (51.8%), with a clinical manifestation being plaque (37%). The most common therapy used in this study was pulse dye laser (PDL) (48.1%). Analysis of the difference in HAS before and after therapy showed p value = 0.00, a statistically significant difference in HAS before and after therapy.

Conclusions: The hemangioma activity score is an effective measurement tool for measuring the severity of IH and evaluating the effectiveness of therapy.

References

  1. Vivcharuk V, Davydenko VY. Influence of age and morphological features on the clinical manifestations and treatment efficacy of hemangiomas in children. Inter Collegas. 2021;8(1), 22-9. doi: https://doi.org/10.35339/ic.8.1.22–29
  2. Pope E, Lara-Corrales I, Sibbald C, Liy-Wong C, Kanigsberg N, Drolet B, Ma J. Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA Pediatrics. 2022;176(1):34-41. doi: 10.1001/jamapediatrics.2021.4565.
  3. Lydiawati E, Zulkarnain I. Infantile Hemangioma: A Retrospective Study. BIKK. 32(1), 21–26. doi: 10.20473/bikk.V32.1.2020.21-26.
  4. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017 Jul 1;390(10089):85-94. doi: 10.1016/S0140-6736(16)00645-0.
  5. MacArthur KM, Putthen K. Vascular Tumors. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, editors. Fitzpatrick’s Dermatology. McGraw-Hill Education. 2019;2042–71.
  6. Dong JY, Ning JX, Li K, Liu C, Wang XX, Li RH, Yue LL, Huang YY, Liu SH. Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. Sci Rep. 2017;7(1):342. doi: 10.1038/s41598-017-00495-z.
  7. Janmohamed SR, de Waard-van der Spek FB, Madern GC, de Laat PC, Hop WC, Oranje AP. Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clin Exp Dermatol. 2011;36(7):715-23. doi: 10.1111/j.1365-2230.2011.04080.x.
  8. Janmohamed SR, van Oosterhout M, de Laat PC, van Rosmalen J, Madern GC, Oranje AP. Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS). J Am Acad Dermatol. 2015;73(2):258-63. doi: 10.1016/j.jaad.2015.05.012.
  9. Janmohamed SR, Oranje AP. Scoring systems for infantile hemangioma: the Hemangioma Activity Score versus the Hemangioma Activity and Severity Index. Int J Dermatol. 2016;55(7):e416-7. doi: 10.1111/ijd.13242.
  10. Ding Y, Zhang JZ, Yu SR, Xiang F, Kang XJ. Risk factors for infantile hemangioma: a meta-analysis. World J Pediatr. 2020;16(4):377-384. doi: 10.1007/s12519-019-00327-2.
  11. Peraturan Menteri Kesehatan Republik Indonesia. Upaya Kesehatan Anak. 2014. Jakarta: Kementrian Keseshatan Republik Indonesia. Available: https://peraturan.bpk.go.id/Home/Details/117562/permenkes-no-25-tahun-2014
  12. Shen L, Zhou G, Zhao J, Li P, Xu Q, Dong Y, Zhang Z. Pulsed dye laser therapy for infantile hemangiomas: a systemic review and meta-analysis. QJM. 2015;108(6):473-80. doi: 10.1093/qjmed/hcu206.
  13. Wu W, Wang H, Hao J, Gao Z, Li F, Chen Y. Therapeutic efficacy of propranolol for infantile hemangiomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(2):132-138. doi: 10.1016/j.oooo.2019.04.014.
  14. Argentina F, Sibero HT. Management of Infantile Hemangioma’. JUKE Jurnal Kedokteran. 2014;4(7):65-74.
  15. Herschthal J, Wulkan A, George M, Waibel J. Additive effect of propranolol and pulsed dye laser for infantile hemangioma. Dermatol Online J. 2013;19(6):18570.

How to Cite

Shavira, P. H. ., Listiawan, M. Y. ., Sawitri, Prakoeswa, C. R. S. ., Rahmadewi, Astari, L. ., Utomo, B. ., & Widianingsih, N. P. S. . (2024). Hemangioma activity score evaluation in infantile hemangioma patients: a retrospective study. Bali Medical Journal, 13(1), 913–917. https://doi.org/10.15562/bmj.v13i1.5284

HTML
0

Total
0

Share

Search Panel

Putri Halla Shavira
Google Scholar
Pubmed
BMJ Journal


Muhammad Yulianto Listiawan
Google Scholar
Pubmed
BMJ Journal


Sawitri
Google Scholar
Pubmed
BMJ Journal


Cita Rosita Sigit Prakoeswa
Google Scholar
Pubmed
BMJ Journal


Rahmadewi
Google Scholar
Pubmed
BMJ Journal


Linda Astari
Google Scholar
Pubmed
BMJ Journal


Budi Utomo
Google Scholar
Pubmed
BMJ Journal


Ni Putu Susari Widianingsih
Google Scholar
Pubmed
BMJ Journal